M&A - Recht und Wirtschaft in der Praxis, Liber Amicorum für Rudolf Tschäni

Published: 14 July 2010

Als einer der ersten Schweizer Anwälte hat Dr. iur. Rudolf Tschäni in den 1980er Jahren erkannt, dass sich die Unternehmensübernahmen im Zuge der Amerikanisierung unserer Rechtskultur zu einem wichtigen selbständigen Rechtsgebiet herausbilden würden. Wie kein anderer Jurist in der Schweiz hat er aufgrund dieser Erkenntnis dieses neue Rechtsgebiet systematisch erschlossen. Dies tat er nicht als Theoretiker im Elfenbeinturm, sondern als praktizierender Rechtsanwalt. Als Autor eines Standardwerks hat es Rudolf Tschäni unternommen, darin eine juristische Gesamtschau zum Thema M&A in der Schweiz vorzunehmen. Das aus Anlass des 60. Geburtstags von Rudolf Tschäni herausgegebene "Liber amicorum" enthält Beiträge von Freunden, Kollegen und Weggefährten, die ihn in seinem rund dreissigjährigen Berufsleben begleitet haben.

Related publications

SEE ALL

Insights

Insights – 04.08.2026

Switzerland steps up: Federal Patent Court affirms cross-border reach in patent litigation

Switzerland steps up: Federal Patent Court affirms cross-border reach in…

<p><strong>Switzerland as a forum for cross-border patent enforcement: the Federal Patent Court confirms its reach</strong></p> <p class="MsoBodyText">In a landmark decision of 17 July 2026 (S2025_003), the Swiss Federal Patent Court has sent a clear signal: Switzerland is very much in the game when it comes to cross-border patent enforcement. The Court confirmed that claims for infringement of foreign patent designations can be heard at the defendant’s Swiss domicile and established a powerful principle of parallel infringement analysis across all EPC member states. For patent holders pursuing multi-jurisdictional strategies, Switzerland must be on the map.</p> <p class="MsoBodyText">The case arose from interim proceedings brought by Regeneron Pharmaceuticals, Inc., Bayer HealthCare LLC and Bayer Consumer Care AG against Sandoz Group AG, Sandoz AG and Sandoz Pharmaceuticals AG. The claimants sought a pan-European injunction against the distribution of Sandoz’ aflibercept biosimilar, relying on both the Swiss designation and multiple foreign designations of a European patent. The case thus presented the Court with a textbook scenario for testing Switzerland’s credentials as a cross-border patent litigation forum.</p> <p class="MsoBodyText">The Court rose to the occasion, delivering clear guidance on two issues that matter for any cross-border patent strategy:</p>

Insights – 30.07.2026

Swiss sanctions and contract law: How far do GTC compliance clauses reach?

Swiss sanctions and contract law: How far do GTC compliance clauses reach?

<p>In its decision 4A_455/2025 of 21 May 2026, the Swiss Supreme Court addressed the extent to which a commercial bank may rely on its general terms and conditions (GTCs) to refuse the release of client assets where performance could expose the bank to sanctions under Swiss or foreign law, and whether such a clause continues to apply after the notice of termination of the banking relationship.</p> <p>The Court held that under Swiss law provisions of a bank’s GTCs may include provisions conditioning performance by the bank to compliance with foreign legal and regulatory requirements and such compliance reservation clauses continue to apply post-termination during the liquidation phase of the account relationship. The judgment further clarifies that a Swiss governing law clause does not preclude the parties from agreeing, through acceptance of GTCs, that performance may be refused in order to comply with foreign legal and regulatory requirements. It also provides important guidance on the assessment of ownership and control for sanctions purposes.</p>
SEE ALL
Lenz & Staehelin {PAGENO}/{nbpg}
{PAGENO}/{nbpg}